Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eli Lilly
Eli Lilly
JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage
Medical Marketing and Media
Thu, 01/11/24 - 11:18 am
JPMHC 2024
obesity
diabetes
diabesity
Novo Nordisk
Eli Lilly
Zepbound shortage could be around the corner
Beckers Hospital Review
Tue, 01/9/24 - 10:05 pm
Eli Lilly
Zepbound
obesity
drug shortages
David Ricks
Pharma CEOs
Alphabet’s Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B ahead of JPM
Fierce Biotech
Sun, 01/7/24 - 04:19 pm
Alphabet
Isomorphic
Eli Lilly
Novartis
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
Reuters
Fri, 01/5/24 - 11:25 am
M&A
JPMHC 2024
AbbVie
AstraZeneca
Bristol Myers Squibb
Carmot Therapeutics
Eli Lilly
Novo Nordisk, Eli Lilly's weight-loss drugs under FDA scrutiny for suicidal thoughts, hair loss
Fierce Pharma
Thu, 01/4/24 - 11:53 am
Novo Nordisk
Eli Lilly
weightloss
side effects
Ozempic
Wegovy
Zepbound
Lilly launches website, home delivery option for weight-loss drugs
Reuters
Thu, 01/4/24 - 10:07 am
Eli Lilly
obesity
Zepbound
Eli Lilly concludes POINT Biopharma acquisition for $1.4bn
Pharmaceutical Business Review
Sun, 12/31/23 - 11:40 am
Eli Lilly
Point Biopharma
M&A
radiopharmaceuticals
Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch
Stat
Thu, 12/21/23 - 09:52 am
obesity
climate change
Wegovy
Zepbound
Novo Nordisk
Eli Lilly
liver disease
Lilly tames Fauna to go on the prowl for obesity targets in $494M deal
Fierce Biotech
Thu, 12/21/23 - 09:37 am
Eli Lilly
Zepbound
obesity
Fauna Bio
Organon pays $50M to pick up rights to pair of Eli Lilly migraine meds in Europe
Fierce Pharma
Mon, 12/18/23 - 10:16 pm
Organon
Eli Lilly
migraines
Europe
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
BioSpace
Mon, 12/18/23 - 10:14 pm
Point Biopharma
Lantheus Holdings
radioligands
prostate cancer
Eli Lilly
Obesity drug Mounjaro to surpass Ozempic with $27 billion sales in 2029
Biopharma Reporter
Mon, 12/18/23 - 11:37 am
Eli Lilly
Novo Nordisk
obesity
weight loss
Ozempic
Mounjaro
Where Will Eli Lilly Be in 5 Years?
Motley Fool
Fri, 12/15/23 - 09:42 am
Eli Lilly
Zepbound
Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound
BioSpace
Mon, 12/11/23 - 10:58 pm
Eli Lilly
weight loss
Zepbound
GLP-1 agonist
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
Motley Fool
Fri, 12/8/23 - 09:56 am
Eli Lilly
Novo Nordisk
weight loss
Wegovy
Zepbound
Eli Lilly’s latest $1.4 billion deal might come unglued
Stat
Thu, 12/7/23 - 11:15 pm
Eli Lilly
Point Biopharma
M&A
Trial finds Lilly’s Olumiant could treat type 1 diabetes
Pharmaphorum
Thu, 12/7/23 - 11:00 am
Eli Lilly
olumiant
type 1 diabetes
Eli Lilly's obesity drug now available in U.S. pharmacies
Reuters
Tue, 12/5/23 - 09:53 am
Eli Lilly
obesity
Zepbound
pharmacies
Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor
BioSpace
Mon, 12/4/23 - 09:41 am
Eli Lilly
FDA
Jaypirca
CLL
small lymphocytic leukemia
Btk inhibitors
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
Reuters
Sun, 12/3/23 - 09:29 pm
Eli Lilly
Zepbound
Novo Nordisk
Wegovy
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »